Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 133Precursor Cell Lymphoblastic Leukemia-Lymphoma 115Myelodysplastic Syndromes 111Leukemia, Lymphocytic, Chronic, B-Cell 101Lymphoma, Non-Hodgkin 97Hodgkin Disease 94Leukemia 85Multiple Myeloma 84Lymphoma 71Lymphoma, Mantle-Cell 66Lymphoma, Follicular 66Lymphoma, Large B-Cell, Diffuse 63Leukemia, Myelogenous, Chronic, BCR-ABL Positive 60Myeloproliferative Disorders 58Lymphoma, B-Cell, Marginal Zone 57Burkitt Lymphoma 52Leukemia, Myelomonocytic, Chronic 51Congenital Abnormalities 50Leukemia, Myeloid, Chronic-Phase 49Lymphoma, Large-Cell, Immunoblastic 45Leukemia, Myeloid, Accelerated Phase 42Hematologic Neoplasms 42Anemia, Refractory, with Excess of Blasts 40Graft vs Host Disease 39Primary Myelofibrosis 36Waldenstrom Macroglobulinemia 33Neoplasms, Plasma Cell 32Blast Crisis 32Lymphoma, T-Cell, Cutaneous 30Recurrence 29

Interventions

Cyclophosphamide 3thymoglobulin 2luspatercept 2fludarabine 2Rituximab 2Melphalan 2Busulfan 2fludarabine phosphate 1Whole-Body Irradiation 1Thiotepa 1Tacrolimus 1Sugammadex 1Mycophenolic Acid 1Levetiracetam 1Dexamethasone 1Bortezomib 1Antilymphocyte Serum 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × beta-Thalassemia × Mycophenolic Acid × Clear all
NCT05736419 2026-06-03

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
24 enrolled
Classical hematology

Anemia, Sickle Cell, Thalassemia, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡